Search research articles
Contact Us
Filters
Showing results (171-180 of 181) with videos related to
Page
of 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 9, 2013
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer
David R Spigel, Thomas J Ervin, Rodryg A Ramlau, et al.
Trials
|
April 29, 2023
ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial
Dana Hartl, Yann Godbert, Xavier Carrat, et al.
Thyroid : Official Journal of the American Thyroid Association
|
November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Thyroid : Official Journal of the American Thyroid Association
|
October 19, 2023
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network
Arnaud Jannin, Fabiola Giudici, Christelle de la Fouchardière, et al.
The Lancet. Diabetes & Endocrinology
|
June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
Clinical Lung Cancer
|
August 12, 2025
AFSOS-SFRO Guidelines on Radiation-Induced Lung Injury
O Cravereau, V Bourbonne, L Vaugier, et al.
Journal for Immunotherapy of Cancer
|
December 5, 2019
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Guillaume Manson, Alexandre Thibault Jacques Maria, Florence Poizeau, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
August 7, 2025
[Recommendations on the prevention and management of radiation-induced lung injury from the Association francophone pour les soins oncologiques de support and the Société française de radiothérapie oncologique]
Olivier Cravéreau, Vincent Bourbonne, Loïg Vaugier, et al.
The New England Journal of Medicine
|
March 9, 2022
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer
Sophie Leboulleux, Claire Bournaud, Cecile N Chougnet, et al.
The Lancet. Diabetes & Endocrinology
|
November 25, 2024
Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial
Sophie Leboulleux, Claire Bournaud, Cecile N Chougnet, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 181) with videos related to
Sort By:
Page
of 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 9, 2013
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer
David R Spigel, Thomas J Ervin, Rodryg A Ramlau, et al.
Trials
|
April 29, 2023
ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial
Dana Hartl, Yann Godbert, Xavier Carrat, et al.
Thyroid : Official Journal of the American Thyroid Association
|
November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Thyroid : Official Journal of the American Thyroid Association
|
October 19, 2023
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network
Arnaud Jannin, Fabiola Giudici, Christelle de la Fouchardière, et al.
The Lancet. Diabetes & Endocrinology
|
June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
Clinical Lung Cancer
|
August 12, 2025
AFSOS-SFRO Guidelines on Radiation-Induced Lung Injury
O Cravereau, V Bourbonne, L Vaugier, et al.
Journal for Immunotherapy of Cancer
|
December 5, 2019
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Guillaume Manson, Alexandre Thibault Jacques Maria, Florence Poizeau, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
August 7, 2025
[Recommendations on the prevention and management of radiation-induced lung injury from the Association francophone pour les soins oncologiques de support and the Société française de radiothérapie oncologique]
Olivier Cravéreau, Vincent Bourbonne, Loïg Vaugier, et al.
The New England Journal of Medicine
|
March 9, 2022
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer
Sophie Leboulleux, Claire Bournaud, Cecile N Chougnet, et al.
The Lancet. Diabetes & Endocrinology
|
November 25, 2024
Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial
Sophie Leboulleux, Claire Bournaud, Cecile N Chougnet, et al.
Page
of 19